<DOC>
	<DOCNO>NCT00035997</DOCNO>
	<brief_summary>The purpose trial Zometa investigate effect ZOMETA 4 mg ( zoledronic acid injection 100mg solution ) preventing associate bone loss prostate cancer patient bone metastasis administer conjunction hormonal cancer therapy . This trial seek determine effect ZOMETA stabilize increase bone mineral density patient . This prospective , open-label , single arm , multicenter study enroll approximately 200 prostate cancer patient history least one document bone lesion document bone scan radiograph . Patients must already receive hormone therapy meet follow additional criterion : - 18 year age old - Histologically confirm diagnosis prostate cancer - Confirmed objective evidence metastatic bone disease evidence bone scan radiograph - Received receive hormonal treatment also know androgen deprivation therapy LHRH agonist hormonal treatment Throughout course 12-month trial , patient identify base duration establish hormonal treatment time enrollment . Each patient duration participation 56 week include 4 week screening , 48 week treatment 4 week follow .</brief_summary>
	<brief_title>Open-label Trial Effect I.V . Zoledronic Acid 4 mg Bone Density Hormone Sensitive Prostate Cancer Patients With Bone Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Inclusion criterion : Signed informed consent Age &gt; 18 year Histologically confirm diagnosis carcinoma prostate Objective evidence metastatic disease bone evidence bone scan radiograph point since diagnosis prostate cancer Currently receive , begin receive , hormonal therapy LHRH agonist hormonal treatment either &lt; 6 month &gt; 6 month ECOG performance status 0 , 1 , 2 Exclusion criterion : Patients hormone sensitive without metastatic disease bone Patients hormone refractory typically define two three consecutive increase PSA measure least one month apart hormone therapy Patients treat LHRH agonist hormonal treatment Patients currently receive diethylstilbestrol ( DES ) PCSPES Patients another nonmalignant disease would confound evaluation primary endpoint prevent patient comply protocol . Patients abnormal renal function evidence either serum creatinine great 2 mg/dL calculate creatinine clearance 60 ml/minute less Corrected ( adjust serum albumin ) serum calcium concentration &lt; 8.0 mg/dl ( 2.00 mmol/L )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Hormone-sensitive Prostate Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Bone Metastasis</keyword>
</DOC>